BioNet and Sartorius’ BIA Separations Collaborate in Developing the Production Process for mRNA Vaccines

0
  • Represents commitment to global efforts against COVID-19 with optimized mRNA production using proprietary chromatographic columns and processes

  • Successful manufacturing process in the production of COVID-19 mRNA

AJDOVŠČINA, Slovenia & BANGKOK, November 02, 2021– (COMMERCIAL THREAD) – BioNet, a leading biotechnology company in the manufacture of genetically modified vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.

BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the development of genetic vaccine products have, since early 2021, enabled the two teams to collaborate on optimization and scaling up. range of a high throughput mRNA production process.

The new process has been successfully applied to the production of mRNA in the fight against COVID-19. The mRNA vaccine, produced at the BioNet manufacturing facility, was developed by the Chula Vaccine Research Center, Thailand, in collaboration with the University of Pennsylvania, USA.

BIA and BioNet are now collaborating on other projects aimed at increasing the development and production capacity of nucleic acid vaccines in Europe, Australia and low and middle income countries.

Hong Thai Pham, CEO of BioNet, said: “We are very pleased to collaborate with BIA Separations / Sartorius in the development and transfer of manufacturing process technologies for optimized mRNA vaccines. When time is of the essence, being able to count on key partners while maintaining the highest level of quality in all aspects of our work. We are also very proud that our team was able to produce two types of genetic vaccines (DNA and mRNA) and we look forward to expanding our partnership with the BIA Separations team on future projects. “

Aleš Štrancar, Managing Director, BIA Separations added: “We are proud to have been selected to support BioNet’s development strategy and it has been a great pleasure to work on their plans to develop an mRNA process. Due to Covid restrictions, all of the work and transfer of technology were coordinated via teleconferences in the absence of meetings and trainings. Despite this, the manufacturing process was developed in just four months, which is close to a miracle. This would not have been possible without the very team. experienced and motivated team of BioNet. In addition, special recognition to our own teams who were, once again, able to develop the manufacturing process in record time “.

For high resolution images, please contact Zyme Communications.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211102005750/en/

Contacts

For more information, please contact:
Zyme Communications
Sarah jeffery
Phone. : +44 (0) 7771 730919
Email: [email protected]

Share.

Comments are closed.